Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. News
  7. Summary
    A096530   KR7096530001


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

07/13/2021 | 08:00am EDT

Seegene Inc. has announced the launch of a new SARS-CoV-2 variant diagnostic test capable of screening newly emerging virus variants including the Delta and the Delta Plus that have become the dominant version of the virus circulating around the world. The company announced on June 30 that it has received the CE-IVD mark for its 'Allplex™ SARS-CoV-2 Variants II Assay,' a new lineup of the company's variant detection kits capable of detecting the key genetic mutations of SARS-CoV-2 variants such as L452R, W152C, K417T and K417N. In a single reaction, the variants diagnostic kit identifies a total of six COVID-19 variants that are known to be originated from India such as Delta, Delta Plus, and Kappa, and Gamma(Brazil), Beta(South Africa), and Epsilon(California). While the number of daily new infections is growing exponentially, the launch of the new assay is expected to play an essential role in monitoring the spread of the Delta and Delta Plus variants that have been largely blamed for the bulk of new infections. Earlier this year, the World Health Organization (WHO) classified the Delta variant as the 'Variant of Concern' as the variant is expected to rapidly outcompete other variants. Also, the emergence of a new mutation on the spike protein of the Delta known as K417N has raised alarm globally, as it is known to be more contagious than the Delta and exhibit vaccine resistance. These super-contagious variants recently have become a global threat. In countries like the UK and Indonesia Delta is the dominant strain accounting for around 90% of new cases. Also, in other countries like the United States, although the variant only made up about 20% of infections, the number appears to be doubling every two weeks. Under such circumstances, the introduction of the 'Allplex™ SARS-CoV-2 Variants II Assay' is receiving much attention from around the world as the assay can screen both Delta and the Delta Plus variant as well as other major COVID-19 variants. The company also announced that it has successfully developed a research-use-only diagnostic tests, 'Allplex™ SARS-CoV-2/P681R Assay,' to precisely target the Delta and Delta Plus variants. According to the company, the conjunction use of the two assays will allow researchers to accurately distinguish the Delta and Delta Plus variants from other genetic mutations.

© S&P Capital IQ 2021
All news about SEEGENE, INC.
09/28Seegene, Inc.'s Equity Buyback announced on March 9, 2021, has expired.
09/27SEEGENE : Unveils Fully Automated Molecular Testing System at the 2021 AACC
09/27Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC
09/01SEEGENE : Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four C..
08/18SEEGENE : Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY
08/18Seegene Inc. Reports Earnings Results for the Second Quarter and First Half Ended June ..
07/13SEEGENE : Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Vari..
07/13Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Var..
07/06SEEGENE : announces partnership with Bio-Rad to develop diagnostic testing products for th..
07/02Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on March 9, 2021.
More news
Sales 2021 1 221 B 1,04 B 1,04 B
Net income 2021 471 B 0,40 B 0,40 B
Net cash 2021 548 B 0,46 B 0,46 B
P/E ratio 2021 5,70x
Yield 2021 7,30%
Capitalization 2 662 B 2 246 M 2 260 M
EV / Sales 2021 1,73x
EV / Sales 2022 2,56x
Nbr of Employees 833
Free-Float 67,9%
Duration : Period :
Seegene, Inc. Technical Analysis Chart | A096530 | KR7096530001 | MarketScreener
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 51 400,00 KRW
Average target price 84 500,00 KRW
Spread / Average Target 64,4%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Hong-Il Yoon Independent Director
Chang-Se Lee Independent Director
Kyung-Jun Chun Director
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-46.74%2 246
GUARDANT HEALTH, INC.-22.84%10 073
BGI GENOMICS CO., LTD.-36.92%5 170